Multiple sclerosis. Part 2: Ophthalmic issues in MS therapy

Current Opinion in Ophthalmology

Volumn 20, Issue 6, 2009, Pages 476-481

  Pula, John H ^a   Javed, Adil ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Multiple sclerosis; Neuro ophthalmology; Ophthalmology; Treatment

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ARTHRALGIA; CARDIOMYOPATHY; CEREBRAL BLINDNESS; DEPRESSION; DIPLOPIA; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FLU LIKE SYNDROME; FLUSHING; GRAVES DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPETENT CELL; INJECTION SITE REACTION; LEUKOPENIA; LIPOATROPHY; LIVER FUNCTION TEST; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; OPTIC NEURITIS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMYELOCYTIC LEUKEMIA; RETINOPATHY; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PEPTIDES;

EID: 74249097999     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283319155     Document Type: Review

References (41)

1. Gay F, Drye T, Dick W, Esiri M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Brain 1997; 120:1461-1483.
2. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
3. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis. Neurology 1996; 46:907-910.
4. Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. Brain 1989; 112:133-146.
5. Optic neuritis study group. Multiple sclerosis risk after optic neuritis. Arch Neurol 2008; 65:727-732. This paper describes 15-year ONTT follow-up data regarding the increased risk of MS occurring if baseline brain MRI shows typical demyelinating white matter lesions.
6. Kaufman D. Acute optic neuritis. Curr Treatment Options Neurol 1999; 1:44-48.
7. Beck R, Gal R. Treatment of acute optic neuritis. Arch Ophthalmol 2008; 126:994-995. Concise summary of evidence-based data for treatment of optic neuritis by Dr Beck, one of the major formulators of the ONTT design.
8. Frohman E, Frohman T, Zee D, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111-121.
9. Biousse V, Calvetti O, Drews-Botsch C, et al. Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci 2009; 276:69-74.
10. Kaufman D, Trobe J, Eggenberger E, Whitaker J. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:2039-2044.
11. Chrousos G, Kattah J, Beck R, Cleary P. Side effects of glucocorticoid treatment: experience of the optic neuritis treatment trial. J Am Med Assoc 1993; 269:2110-2112. (Pubitemid 23112630)
12. Filippini G, Brusaferri F, Sibley W, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000: CD001331.
13. Perumal J, Caon C, Hreha S, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008; 15:677-680. This paper describes a trial that questions whether oral prednisone taper is required after high dose steroids in acute optic neuritis.
14. Noseworthy J, O'Brien P, Petterson T, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56:1514-1522.
15. Roed H, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804-810.
16. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15:1163-1167. A re-examination of the use of IVIg in acute optic neuritis. Unlike prior studies showing nonefficacy, this study showed a benefit.
17. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis. Neurology 2004; 63:1081-1083.
18. Javed A, Reder A. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Therapeut 2006; 110:35-56.
19. Weber M, Hohlfeld R, Zamvil S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007; 4: 647-653. (Pubitemid 47499292)
20. Mikol D, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open-label trial. Lancet Neurol 2008; 7:903-914.
21. Cadavid D, Wolansky L, Skurnick J, et al. Efficacy of treatment of MS with IFN(beta) or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009. [Epub ahead of print]
22. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002; 359:1453-1460.
23. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005; 239:67-74.
24. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79:52-56.
25. Arnold D, Campagnolo D, Panitch H, et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008; 255:1473-1478.
26. Paul F, Waiczies S, Wuerful J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008; 3:e1928.
27. Birnbaum G, Cree B, Altafullah I, et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008; 71:1390-1395.
28. Patten S, Williams J, Metz L. Antidepressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Multiple Sclerosis 2008; 14:406-411.
29. Miller A, Spada V, Beerkircher D, Kreitman R. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsingremitting multiple sclerosis. Multiple Sclerosis 2008; 14:494-499.
30. Saito H, Suzuki M, Asakawa T, Kato S. Retinopathy in a multiple sclerosis patient undergoing interferon-therapy. Multiple Sclerosis 2007; 13:939-940.
31. Folden D, Lee M, Ryan E. Interferon b-associated retinopathy in patients treated for multiple sclerosis. Neurology 2008; 70:1153-1155.
32. Polman C, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
33. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8:254-260. This study confirmed the significant benefit of natalizumab used for active MS.
34. Goodin D, Cohen B, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Neurology 2008; 71:766-773.
35. Khatri B, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72:402-409.
36. Bosca I, Pascual A, Casanova B, et al. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 2008; 71:457-458.
37. Ko M, Tamhankar M, Volpe N, et al. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci 2008; 273:144-147.
38. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786-1801.
39. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis. Neurology 2009; 72:73-79.
40. Giovannoni G. Presented at the American Academy of Neurology Annual Meeting; 30 April 2009; Seattle, WA.
41. Burt R, Loh Y, Cohen B, et al. Autologous nonmyeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis a phase I/II study. Lancet Neurol 2009; 8:244-253. This study showed that reinfusion of hematopoietic peripheral blood stem cells in conjunction with other chemotherapy improved patient EDSS scores.